Photo of C. Ola Landgren taken from news.med.miami.edu
Aug 2, 2024, 23:39
The efficacy of BMA and the role of precision medicine in Myeloma
C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, shared a post by HealthTree Foundation on X, adding:
“Thank you HealthTree Foundation for the interview at EHA2024 on bispecific monoclonal antibodies in myeloma. Lots of exciting new data. Great for patients!”
Quoting HealthTree Foundation‘s post:
“MYELOMA: C. Ola Landgren, MD discusses the efficacy of bispecific antibodies and the role of precision medicine in managing this complex disease.”
Source: C. Ola Landgren/X and HealthTree Foundation/X